Horizon Therapeutics has had the thyroid eye disease space to itself for a couple of years, but competition could soon be coming. And Viridian’s contender VRDN-001 might have the edge when it comes to efficacy, early data released yesterday suggest.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,